| Literature DB >> 32127805 |
Roland Nnaemeka Okoro1, Chijioke Nmeka2, Patrick O Erah3.
Abstract
BACKGROUND: Subsidizing the cost of medicines through insurance schemes increases consumption of medicines and may contribute to irrational use of antibiotics.Entities:
Keywords: Antibiotics; Nigeria; national health insurance scheme; poly-pharmacy; prescription
Mesh:
Substances:
Year: 2019 PMID: 32127805 PMCID: PMC7040270 DOI: 10.4314/ahs.v19i3.8
Source DB: PubMed Journal: Afr Health Sci ISSN: 1680-6905 Impact factor: 0.927
Antibiotics prescribing indicators
| Medicine Prescribing Indicator | Value |
| Average number of medicines per prescription (Mean ± SD) | 4.0 ± 1.8 |
| Average number of antibiotics per encounter(Mean ± SD) | 1.3 ± 0.5 |
| Percentage of antibiotics prescribed by generic name (%) | 46.9 |
| Percentage of antibiotics prescribed from NHIS EML (%) | 82.9 |
| Percentage of antibiotics dispensed (%) | 72.4 |
SD = Standard Deviation
Distribution of prescribed antibiotics in various age groups, gender and period of the year
| Variable | Antibiotics Prescribed n (%) | |
| <5 | 20 (9.5) | |
| 5–11 | 25 (11.8) | |
| 12–59 | 153 (72.5) | |
| ≥60 | 13 (6.2) | |
| Female | 121 (57.3) | |
| Male | 90 (42.7) | |
| 1st Quarter | 65 (30.8) | |
| 2nd Quarter | 73 (34.6) | |
| 3rd Quarter | 62 (29.4) | |
| 4th Quarter | 11 (5.2) |
Overall antibiotics prescription patterns (N =275)
| Antibiotic Class n (%) | Antibiotic Name | n (%) |
| Amoxicillin+Clavulanate | 87 (31.6) | |
| Amoxicillin | 21(7.6) | |
| Ampicillin+Cloxacillin | 7 (2.5) | |
| Flucloxacillin | 3 (1.1) | |
| Ampicillin+Sulbactam | 1 (0.4) | |
| Metronidazole Secinidazole | 48 (17.5) 10 (3.6) | |
| Tinidazole | 3 (1.1) | |
| Ciprofloxacin Levofloxacin | 36 (13.1) 14 (5.1) | |
| Ofloxacin | 5 (1.8) | |
| Erythromycin Azithromycin | 6 (2.2) 5 (1.8) | |
| Clarithromycin | 3 (1.1) | |
| Cefixime | 6 (2.2) | |
| Cefpodoxime | 4 (1.4) | |
| Cefuroxime | 3 (1.1) | |
| Cephalexin | 1 (0.4) | |
| Doxycycline Tetracycline | 4 (1.4) 1 (0.4) | |
| Cotrimoxazole | 5 (1.8) | |
| Clindamycin | 1 (0.4) |
Prescribed antibiotics mono- and combination therapies
| Variable | Antibiotics | n (%) |
| Amoxicillin/Clavulanate | 64 (43.0) | |
| Ciprofloxacin | 24 (16.1) | |
| Amoxicillin | 13 (8.7) | |
| Ampicillin/Cloxacillin | 6 (4.0) | |
| Erythromycin | 6 (4.0) | |
| Cefixime | 5 (3.4) | |
| Levofloxacin | 5 (3.4) | |
| Others | 26(17.4) | |
| Amoxicillin/Clavulanate+Metronidazole | 19 (31.8) | |
| Ciprofloxacin+Metronidazole | 11(18.3) | |
| Amoxicillin+Metronidazole | 7 (11.7) | |
| Levofloxacin + Secinidazole | 6 (10.0) | |
| Amoxicillin/Clavulanate+ Secinidazole | 2 (3.3) | |
| Cefpodoxime+Metronidazole | 2 (3.3) | |
| Doxycycline+Metronidazole | 2 (3.3) | |
| Others | 11(18.3) | |
| Doxycycline+Metronidazole+Levofloxacin | 2 (100.0) |
Determinants of antibiotic exposure
| Variable | OR (95% CI) | P value | |
| <5 | Reference | ||
| 5–11 | 0.70 (0.32 – 1.50) | 0.350 | |
| 12–59 | 0.44 (0.24 – 0.83) | 0.006 | |
| ≥60 | 0.21 (0.09 – 0.50) | 0.001 | |
| Women | Reference | ||
| Men | 1.26 (0.92 – 1.74) | 0.152 | |
| 1st Quarter | Reference | ||
| 2nd Quarter | 0.79 (0.54 – 1.17) | 0.237 | |
| 3rd Quarter | 0.92 (0.61 – 1.39) | 0.690 | |
| 4th Quarter | 1.16 (0.54 – 2.50) | 0.711 | |
| 1–2 | Reference | ||
| 3–4 | 1.63 (1.02 – 2.62) | 0.042 | |
| ≥5 | 2.20 (1.37 . 3.55) | 0.001 |
Significant at P < 0.05